These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37888905)

  • 1. Tumor-Agnostic Treatment Heading to the Clinic?
    Cancer Discov; 2023 Dec; 13(12):OF10. PubMed ID: 37888905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2-Targeted Therapy Shows Promise across Tumor Types.
    Cancer Discov; 2023 Aug; 13(8):OF3. PubMed ID: 37279357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations.
    Rolfo C; Del Re M; Russo A
    Clin Cancer Res; 2023 Nov; 29(21):4317-4319. PubMed ID: 37656059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting HER2 expression in cancer: New drugs and new indications.
    Vranić S; Bešlija S; Gatalica Z
    Bosn J Basic Med Sci; 2021 Feb; 21(1):1-4. PubMed ID: 32530388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Gives Nod to T-DXd for HER2-Mutant NSCLC.
    Cancer Discov; 2022 Oct; 12(10):2224. PubMed ID: 35984233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting HER2 May Overtake Chemo, Immunotherapy in NSCLC.
    Cancer Discov; 2021 Dec; 11(12):OF3. PubMed ID: 34675060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
    Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
    Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer.
    Makhlin I; DeMichele A
    Cell Rep Med; 2022 Jun; 3(6):100668. PubMed ID: 35732147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
    Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
    Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
    Nakano K
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
    Hingorani P; Zhang W; Zhang Z; Xu Z; Wang WL; Roth ME; Wang Y; Gill JB; Harrison DJ; Teicher BA; Erickson SW; Gatto G; Kolb EA; Smith MA; Kurmasheva RT; Houghton PJ; Gorlick R
    Mol Cancer Ther; 2022 Aug; 21(8):1318-1325. PubMed ID: 35657346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan.
    Shukla ND; Chiang RS; Colevas AD
    J Natl Compr Canc Netw; 2022 Feb; 20(2):102-104. PubMed ID: 35130504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
    Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Yamaguchi K;
    N Engl J Med; 2020 Jun; 382(25):2419-2430. PubMed ID: 32469182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
    Jørgensen JT
    Oncology; 2023; 101(12):836-842. PubMed ID: 37651992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
    Tsurutani J; Iwata H; Krop I; Jänne PA; Doi T; Takahashi S; Park H; Redfern C; Tamura K; Wise-Draper TM; Saito K; Sugihara M; Singh J; Jikoh T; Gallant G; Li BT
    Cancer Discov; 2020 May; 10(5):688-701. PubMed ID: 32213540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Mallet A; Ombline C; Robert M; Campone M; Frenel JS
    Bull Cancer; 2021 Dec; 108(11S):11S19-11S25. PubMed ID: 34969512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
    Indini A; Rijavec E; Grossi F
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Trastuzumab-deruxtecan monotherapy in HER2-activated advanced non-small cell lung cancer pre-treated with platinum-based chemotherapy with or without immunotherapy].
    Rivier C; Lavaud P
    Bull Cancer; 2024 Jun; 111(6):539-540. PubMed ID: 38553285
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.